On April 25, Ge Longhui (688382.SH) released its 2023 annual report. During the reporting period, the company made every effort to promote clinical research and cooperative development of major products and made important progress. In 2023, it achieved operating income of 186 million yuan, net profit attributable to shareholders of listed companies - 284 million yuan, a year-on-year loss decrease of 41.26%. The loss margin was narrower compared to the same period last year, mainly due to the increase in the company's 2023 technical licensing and technical cooperation revenue.
益方生物(688382.SH)：2023年净利润-2.84亿元
Yifang Biotech (688382.SH): 2023 net profit - $284 million
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.